retatrutide triple G 4 mg (Retatrutyd) Retatrutide: The "Triple G" Peptide
Description
It is a once-daily subcutaneous injection
Injectable semaglutide and dulaglutide have demonstrated robust A1C reductions along with well-established cardiovascular benefits
Timeline and Next Steps February 21, 2025: The FDA officially removes semaglutide from the drug shortage list
The survey found that 57% were more interested in seeing GLP-1s approved for sleep apnea, followed by 56% for chronic heart failure, 47% for NASH, and 37% for chronic kidney disease
When traveling, use a portable insulated cooler bag with ice packs or a cooling device designed for medications
